quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:38:29·23d
SECFiling
Teva Pharmaceutical Industries Limited logo

SEC Form DEF 14A filed by Teva Pharmaceutical Industries Limited

TEVA· Teva Pharmaceutical Industries Limited
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • TEVA
    Teva Pharmaceutical Industries Limited
    Health Care

Recent analyst ratings

  • Dec 9UpdateBarclays$35.00
  • Dec 5UpdateScotiabank$35.00
  • Jun 6UpdateGoldman$24.00
  • May 28UpdateTruist$25.00
  • May 12UpdateAnalyst$23.00
  • Jul 10UpdateArgus$20.00

Related

  • PR8d
    Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
  • SEC23d
    SEC Form DEFA14A filed by Teva Pharmaceutical Industries Limited
  • PR24d
    Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
  • PR35d
    Teva Releases Q1 2026 Aide Memoire
  • PR35d
    Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
  • INSIDER35d
    SEC Form 4 filed by Sabag Mark
  • INSIDER45d
    See "Remarks" Sabag Mark converted options into 15,723 units of Ordinary Shares, increasing direct ownership by 6% to 287,042 units (SEC Form 4)
  • INSIDER45d
    EVP, Chief Financial Officer Kalif Eliyahu Sharon converted options into 19,916 units of Ordinary Shares, increasing direct ownership by 7% to 325,435 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022